

LIST OF TABLES

Table No.	Description	Page No.
Chapter - 1		
1.1	Classification of genotoxic impurities as per ICH M7 guidelines	3
Chapter – 2		
2.1	Literature survey on different methods using different liquid chromatography and spectroscopic techniques for atazanavir sulphate and its impurities	17
2.2	Literature review on different techniques for erlotinib and its impurities	18
2.3	Literature survey on different methods for imatinib mesylate and its impurities	20
2.4	Literature survey on different methods using different techniques for pantoprazole and its impurities	22
2.5	Literature survey for albendazole and its impurities	24
2.6	Literature survey on different technique for genotoxic impurities	25
Chapter-3		
3.1	List of standards and chemicals	29
3.2	Listing of Instrument/ Equipment	31
3.3	LC and Mass parameters for BOC epoxide content	32
3.4	Accuracy data for BOC epoxide	36
3.5	Linearity data for BOC epoxide	37
3.6	System suitability results	39
3.7	Method precision and intermediate precision of BOC epoxide	40
3.8	Robustness data at various conditions	40
3.9	Robustness data for flow rate changes	41
3.10	Robustness data for column temperature changes	41
3.11	Solution stability for BOC epoxide and spiked sample	42
Chapter-4		
4.1.1	List of standards and chemicals	44
4.1.2	LC and mass parameters for genotoxic impurities in erlotinib	48
4.1.3	System suitability results	49

4.1.4	LOD and LOQ data for both GTI's	50
4.1.5	Linearity data for both GTI's	51
4.1.6	Accuracy data for both GTI's	53
4.1.7	The precision data for both GTI's	54
4.1.8	Robustness data for various flow rates	55
4.1.9	Robustness data for various column temperatures	55
4.1.10	The solution stability data for both GTI's and spiked sample at different conditions	56
4.2.1	List of standards and chemicals	58
4.2.2	LC and mass parameters for IMT-01 content in Imatinib mesylate.	61
4.2.3	Accuracy data for IMT-01	65
4.2.4	Linearity data for IMT-01	66
4.2.5	System suitability results	67
4.2.6	Precision data for IMT-01	68
4.2.7	Robustness data for flow rate changes	69
4.2.8	Robustness data for column temperature changes	69
4.2.9	Robustness data at various conditions	70
4.2.10	Solution stability of both IMT-01 and spiked sample	70
Chapter-5		
5.1	List of standards and chemicals	74
5.2	LC parameters for genotoxic impurities in pantoprazole sodium	77
5.3	Gradient programme	77
5.4	Mass parameters for genotoxic impurities in pantoprazole sodium	78
5.5	LOD and LOQ data for three genotoxic impurities	79
5.6	Linearity data for GTI's	80
5.7	Recovery data for GTI's	82
5.8	System suitability results	84
5.9	Results of precision data	85
5.10	Robustness data for GTI-A	86
5.11	Robustness data for GTI-B	86
5.12	Robustness data for GTI-C	87

5.13	The solution stability data for three genotoxic impurity solutions and spiked sample	88
------	--	----

Chapter-6

6.1	List of standards and chemicals	90
6.2	LC and mass parameters for genotoxic impurities in albendazole	94
6.3	System suitability results	95
6.4	LOD and LOQ data for both GTI's	97
6.5	Accuracy data for GTI-I and GTI-II	98
6.6	Method precision and intermediate precision for GTI-I and GTI-II	100
6.7	Robustness data for various flow rates	101
6.8	Robustness data for various column temperatures	101
6.9	The solution stability data for both GTI's and spiked sample at different time intervals.	102

Chapter-7

7.1	Validation summary for BOC epoxide in atazanavir sulphate	103
7.2	Validation summary for ERL ethyl ester and ERL nitro compound in erlotinib hydrochloride	104
7.3	Validation parameters for IMT-01 content in imatinib mesylate	105
7.4	Validation summary for three potential genotoxic impurities in pantoprazole sodium	106
7.5	Validation summary for two potential genotoxic impurities in albendazole	107

LIST OF FIGURES

Fig. No.	Description	Page No.
Chapter-1		
1.1	Assessment decision tree for genotoxic impurities	3
1.2	Structure alerting some functional groups	4
1.3	ESI schematic diagram	7
1.4	APCI schematic diagram	7
1.5	Quadrupole mass analyzer	8
1.6	Schematic diagram of a triple quadrupole mass analyser	9
1.7	Schematic diagram of electron multiplier	10
1.8	Limit of detection and limit of quantization through S/N ratio	14
Chapter-3		
3.1	The structure of Atazanavir Sulphate and BOC epoxide	27
3.2	Blank chromatogram for specificity	34
3.3	Atazanavir chromatogram for specificity	34
3.4	BOC epoxide chromatogram for specificity	34
3.5	LOD chromatogram of BOC epoxide	35
3.6	LOQ chromatogram of BOC epoxide	35
3.7	Accuracy at LOQ level chromatogram	36
3.8	Linearity graph and corresponding chromatograms	38
Chapter-4		
4.1.1	The structure of erlotinib hydrochloride	43
4.1.2	The structure of two genotoxic impurities	44
4.1.3	Ethyl 2-amino-4,5-bis(2-methoxyethoxy) benzoate linearity graph	50
4.1.4	Ethyl 4,5-bis(2-methoxyethoxy) benzoate linearity graph	51
4.1.5	LOQ accuracy chromatogram for Ethyl 2-amino-4,5-bis(2-methoxyethoxy) benzoate	52
4.1.6	LOQ accuracy chromatogram for Ethyl 4,5-bis(2-methoxyethoxy) benzoate	52
4.2.1	The structure of imatinib mesylate	57
4.2.2	The structure of IMT-01	58

4.2.3	Blank chromatogram for specificity	63
4.2.4	Imatinib chromatogram for specificity	63
4.2.5	IMT-01 chromatogram for specificity	64
4.2.6	LOQ level accuracy chromatogram	65
4.2.7	Linearity graph for IMT-01	66

Chapter-5

5.1	The structure of pantoprazole sodium sesquihydrate	72
5.2	The structure of three genotoxic impurities	73
5.3	Specificity chromatogram	79
5.4	Linearity graph for N-(4-hydroxyphenyl) acetamide	80
5.5	Linearity graph for N-(4-(difluoromethoxy) phenyl) acetamide	81
5.6	Linearity graph for 4-(difluoromethoxy)-2-nitroaniline	81
5.7	Sample chromatogram	83
5.8	Accuracy at LOQ level chromatogram	83

Chapter-6

6.1	The structure of albendazole	89
6.2	The structure of GTI-I and GTI-II	90
6.3	Specificity chromatogram for blank	96
6.4	Specificity chromatograms for albendazole, GTI-I and GTI-II	96
6.5	GTI-I linearity graph	97
6.6	GTI-II linearity graph	98
6.7	Accuracy chromatogram for GTI-I and GTI-II	99

LIST OF ABBREVIATIONS

PGIs	Potential genotoxic impurities
ppm	Parts per million
HPLC	High performance liquid chromatography
RP-HPLC	Reverse phase-High performance liquid chromatography
UPLC	Ultra performance liquid chromatography
GC	Gas chromatography
API	Active pharmaceutical ingredient
ICH	International conference on harmonization
MS	Mass spectrometry
NMR	Nuclear magnetic resonance
GC-MS	Gas chromatography mass spectrometry
DNA	Deoxyribonucleic acid
HIV	Human immunodeficiency virus
g	Gram
µg	Microgram
µl	Micro liter
mg	Milligram
µm	Micrometer
mm	Millimeter
v/v	Volume by volume
°C	Degree Celsius
USFDA	Us food and drug administration
LC	Liquid chromatography
TLC	Thin layer chromatography
X-RPD	X-Ray powder diffraction
UV	Ultraviolet
APCI	Atmospheric pressure chemical ionization
ESI	Electro spray ionization
MCASE	Multi computer automated structure evaluation
DEREK	Deductive estimation of risk from existing knowledge
TTC	Threshold of toxicological concern
EMA	European medicines agency

LC-MS	Liquid chromatography- mass spectrometry
TOF	Time of flight
m/z	Mass to charge ratio
USP	United states pharmacopeia
RSD	Relative standard deviation
LOD	Limit of detection
LOQ	Limit of quantification
GTIs	Genotoxic impurities
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
USFDA	Us food and drug administration
mL	Milliliter
hr	Hour
et al.	Co-workers
CAS	Chemical abstract service
FDA	Food and drug administration
Min	Minutes
SIM	Single ion monitoring
MRM	Multiple reaction monitoring
RT	Run time
r	Correlation coefficient
Std. dev.	Standard deviation
S/N ratio	Signal to noise ratio
Conc.	Concentration